Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Top Cited Papers
Open Access
Abstract
Standard chemotherapy for newly diagnosed ovarian cancer is a platinum–taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer.

This publication has 23 references indexed in Scilit: